EP4100010A4 - Zusammensetzungen und verfahren zur dämpfung von opioid-induzierter herz- und/oder atemdepression - Google Patents

Zusammensetzungen und verfahren zur dämpfung von opioid-induzierter herz- und/oder atemdepression Download PDF

Info

Publication number
EP4100010A4
EP4100010A4 EP21750608.8A EP21750608A EP4100010A4 EP 4100010 A4 EP4100010 A4 EP 4100010A4 EP 21750608 A EP21750608 A EP 21750608A EP 4100010 A4 EP4100010 A4 EP 4100010A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
respiratory depression
opioid induced
attenuating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP21750608.8A
Other languages
English (en)
French (fr)
Other versions
EP4100010A1 (de
EP4100010B1 (de
Inventor
Stephen J. Lewis
James M. Seckler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of EP4100010A1 publication Critical patent/EP4100010A1/de
Publication of EP4100010A4 publication Critical patent/EP4100010A4/de
Application granted granted Critical
Publication of EP4100010B1 publication Critical patent/EP4100010B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
EP21750608.8A 2020-02-07 2021-02-08 Nitroxidverbindungen zur verwendung bei der behandlung von opioidinduzierter atemdepression (oird) Active EP4100010B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062971675P 2020-02-07 2020-02-07
PCT/US2021/017088 WO2021159077A1 (en) 2020-02-07 2021-02-08 Compositions and methods for attenuating opioid induced cardio and/or respiratory depression

Publications (3)

Publication Number Publication Date
EP4100010A1 EP4100010A1 (de) 2022-12-14
EP4100010A4 true EP4100010A4 (de) 2024-02-14
EP4100010B1 EP4100010B1 (de) 2026-01-07

Family

ID=77200789

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21750608.8A Active EP4100010B1 (de) 2020-02-07 2021-02-08 Nitroxidverbindungen zur verwendung bei der behandlung von opioidinduzierter atemdepression (oird)

Country Status (4)

Country Link
EP (1) EP4100010B1 (de)
AU (1) AU2021217223B2 (de)
CA (1) CA3167312A1 (de)
WO (1) WO2021159077A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025123013A1 (en) * 2023-12-08 2025-06-12 Case Western Reserve University Compositions for treating addiction, dependence, withdrawal, and/or opioid induced hyperalgesia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (de) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
US20090062338A1 (en) * 2005-02-02 2009-03-05 Louis Habash Nitroxides for use in treating or preventing cardiovascular disease
US9561177B2 (en) * 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10881633B2 (en) * 2015-01-13 2021-01-05 Case Western Reserve University Compositions and methods for stimulating ventilatory and/or respiratory drive
WO2018093666A1 (en) * 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALGERA MARIJKE HYKE ET AL: "Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal", BRITISH JOURNAL OF ANAESTHESIA, vol. 122, no. 6, 1 June 2019 (2019-06-01), pages e168 - e179, XP093112583, ISSN: 0007-0912, DOI: 10.1016/j.bja.2018.12.023 *

Also Published As

Publication number Publication date
EP4100010A1 (de) 2022-12-14
CA3167312A1 (en) 2021-08-12
AU2021217223A1 (en) 2022-09-01
AU2021217223B2 (en) 2026-04-23
WO2021159077A1 (en) 2021-08-12
EP4100010B1 (de) 2026-01-07

Similar Documents

Publication Publication Date Title
SG11202106392RA (en) Combination of dextromethorphan and bupropion for treating depression
IL294066A (en) Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
IL308221A (en) Preparations and methods for treating depression
IL289731A (en) Methods for treating or preventing asthma by administering an antagonist to il-4r
EP4069262A4 (de) Verfahren zur dezellularisierung und rezellularisierung von organen und teilen von organen
EP3996786A4 (de) Beatmungsanordnung und verfahren zur verwendung davon
EP3836953A4 (de) Zusammensetzungen und verfahren zur behandlung von akuter lungenläsion
EP4034134A4 (de) Zusammensetzungen und verfahren zum wiederherstellen oder erhöhen der gewebeperfusion
EP4138862A4 (de) Zusammensetzungen und verfahren zur behandlung von infektionen der oberen atemwege
EP4317176A4 (de) Impfstoffzusammensetzung auf basis eines abgeschwächten reovirus und verwendung davon
EP4025258A4 (de) Verfahren und zusammensetzungen zur behandlung von als
GB201913956D0 (en) Inhalable cannabinoid compositions and uses
HK40084664A (en) Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
HK40104263A (en) Opioid sparing compositions and methods of using the same
AU2021900250A0 (en) Opioid sparing compositions and methods of using the same
AU2021900147A0 (en) Opioid sparing compositions and methods of using the same
HK40080120A (en) Compositions and methods for treating upper respiratory infections
AU2019900514A0 (en) Compositions and methods for treating respiratory diseases
CA3280255A1 (en) Methods and compositions for combination therapy
CA3280256A1 (en) Methods and compositions for combination therapy
HK40107055A (en) Compositions and methods for the treatment of depression
HK40116234A (en) Injectable and inhalable formulations
CA3256197A1 (en) COMPOSITIONS AND PROCESSES FOR INHALABLE THERAPEUTIC AGENTS
AU2019903734A0 (en) Inhalable compositions and uses thereof
HK40087581A (en) Methods and compositions for treating acute lung injury and acute respiratory distress syndrome

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4535 20060101ALI20240111BHEP

Ipc: A61K 31/4468 20060101ALI20240111BHEP

Ipc: A61K 31/40 20060101ALI20240111BHEP

Ipc: A61P 9/02 20060101ALI20240111BHEP

Ipc: A61P 11/00 20060101ALI20240111BHEP

Ipc: A61P 25/36 20060101ALI20240111BHEP

Ipc: C07D 211/94 20060101ALI20240111BHEP

Ipc: A61K 31/452 20060101ALI20240111BHEP

Ipc: A61K 31/45 20060101ALI20240111BHEP

Ipc: A61K 31/445 20060101AFI20240111BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241128

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250806

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260107

Ref country code: GB

Ref legal event code: FG4D

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0015727_4100010/2025

Effective date: 20251204

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021045991

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260326

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20260320

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20260324

Year of fee payment: 6

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20260107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1875222

Country of ref document: AT

Kind code of ref document: T

Effective date: 20260107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260408

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260507

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260507

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260107